Skip to content Skip to navigation



According to the Food and Drug Administration (FDA) it takes an average of 12 years from submission of an application to the approval of a drug in the United States. While exhaustive investigations into novel therapeutic are mandated in order to mitigate both long- and short-term safety and efficacy issues, the process of standard drug application and approvals is not designed for active biological threats - a lesson humanity has painfully endured during the current COVID-19 pandemic.  

Preliminary results of favapiravir (Avigan) has demonstrated in some effectiveness in COVID-19 patients in a Kuwait study.  Dr. Richard Kaszynski (Stanford Solutions) worked with the Kuwaiti Ministry of health to help design the study and implement protocols. The majority of patients who were given Avigan tested negative for the COVID-19 virus within five days of treatment. 

Read article here

Stanford Solution’s Director of International Projects, Dr. Richard Kaszynski, served as the chief speaker in the “Current Concepts on role of Favipiravir in Managing COVID-19” Symposium. The symposium was hosted by Dr. Reddy’s Laboratories, an Indian international pharmaceutical corporation based in Hyderabad. Dr. Kaszynski shared his clinical insight on the efficacy of Favipiravir, also known as Avigan, in treating COVID-19 patients with more than 2000 physicians across the United States in attendance. Overall, the symposium received much positive reception as Dr.

Last year, when I visited the town of Beni, in the Democratic Republic of the Congo (DRC), people did not shake hands. Bottles of disinfectant and buckets of chlorinated water were at the entrance of every business. Misinformation spread across social networks and on news-sites, and treatment centers in the northeastern province of North Kivu were being attacked by armed militias.

The World Health Organization said parents need to prepare their kids to guard against COVID-19 after a new study showed that babies and very young children can sometimes develop severe symptoms.

A recent study showed that a number of children in China have developed severe or critical disease and one child has died, said Dr. Maria Van Kerkhove, head of WHO’s emerging diseases and zoonosis unit, at a news conference on Wednesday. “What we need to prepare for is the possibility that children can also experience severe disease.”